Evidence map›Paper›PMID 31415679›Full record

ArticlePLoS pathogens2019

STING is required for host defense against neuropathological West Nile virus infection.

Kathryn McGuckin Wuertz, Piper M Treuting, Emily A Hemann, Katharina Esser-Nobis, Annelise G Snyder, Jessica B Graham, Brian P Daniels, Courtney Wilkins, Jessica M Snyder, Kathleen M Voss and 3 more

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 45 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. The Many Ways to Deal with STING.International journal of molecular sciences · 2023
    Review
  7. Article
  8. Interplay between RNA viruses and cGAS/STING axis in innate immunity.Frontiers in cellular and infection microbiology · 2023
    Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Kathryn McGuckin WuertzDepartment of Global Health, University of Washington, Seattle, WA, United States of America.ORCID 0000-0003-2658-6284
Piper M TreutingDepartment of Comparative Medicine, University of Washington, Seattle, WA, United States of America.ORCID 0000-0002-1812-1519
Emily A HemannDepartment of Immunology, University of Washington, Seattle, WA, United States of America.ORCID 0000-0002-6398-3492
Katharina Esser-NobisDepartment of Immunology, University of Washington, Seattle, WA, United States of America.
Annelise G SnyderDepartment of Immunology, University of Washington, Seattle, WA, United States of America.ORCID 0000-0002-3038-8099
Jessica B GrahamVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States of America.
Brian P DanielsDepartment of Cell Biology and Neuroscience, Rutgers University, Piscataway, NJ, United States of America.
Courtney WilkinsCenter for Innate Immunity and Immune Disease, University of Washington, Seattle, WA, United States of America.ORCID 0000-0003-4001-7686
Jessica M SnyderDepartment of Comparative Medicine, University of Washington, Seattle, WA, United States of America.ORCID 0000-0002-0470-0931
Kathleen M VossDepartment of Immunology, University of Washington, Seattle, WA, United States of America.ORCID 0000-0003-1033-7670
Andrew OberstDepartment of Immunology, University of Washington, Seattle, WA, United States of America.
Jennifer LundVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States of America.ORCID 0000-0003-3284-979X
Michael GaleDepartment of Global Health, University of Washington, Seattle, WA, United States of America.ORCID 0000-0002-6332-7436
University of Washington · USFred Hutch Cancer Center · USRutgers, The State University of New Jersey · USUnited States Department of Defense · US

Funding

Washington National Primate Research CenterP51OD010425 · OD · UNIVERSITY OF WASHINGTON · PI Mari Ostendorf · 2012 to 2026
$201.8M
Unlocking Zika Virus Immune Control and Pathogenesis with the Collaborative CrossU19AI100625 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI MCWEENEY, SHANNON K. · 2012 to 2021
$36.6M
West Nile Virus and host control of innate defensesU19AI083019 · NIAID · UNIVERSITY OF WASHINGTON · PI CLARK, EDWARD A · 2009 to 2018
$22.5M
TRAINING IN MOLECULAR AND CELLULAR BIOLOGYT32GM007270 · NIGMS · UNIVERSITY OF WASHINGTON · PI RAIBLE, DAVID W · 1985 to 2020
$21.0M
Innate Immune Antivirals for BiodefenseR01AI098943 · NIAID · UNIVERSITY OF WASHINGTON · PI GALE, MICHAEL · 2012 to 2016
$8.0M
Diseases of Public Health Importance Training GrantT32AI007509 · NIAID · UNIVERSITY OF WASHINGTON · PI LUND, JENNIFER M · 1997 to 2024
$6.3M
Innate Immune Control of West Nile VirusR01AI104002 · NIAID · UNIVERSITY OF WASHINGTON · PI DIAMOND, MICHAEL S, GALE, MICHAEL · 2013 to 2017
$3.7M
The Role of the RIP Kinases in Coordinating Neuroinflammation and Host DefenseR01AI132595 · NIAID · UNIVERSITY OF WASHINGTON · PI OBERST, ANDREW ATWELL · 2018 to 2022
$2.2M
GENE EXPRESSION IN THE PASMODIUM FALCIPARUM PLASTIDF32AI010042 · NIAID · SEATTLE BIOMEDICAL RESEARCH INSTITUTE · PI GILLESPIE, DOREEN E · 1998 to 1998
–
NIAID NIH HHS F32 AI010042NIAID NIH HHS R01 AI098943NIAID NIH HHS R01 AI104002NIAID NIH HHS R01 AI132595NIAID NIH HHS T32 AI007509NIAID NIH HHS U19 AI083019NIAID NIH HHS U19 AI100625NIGMS NIH HHS T32 GM007270NIH HHS P51 OD010425
6 · The paper itself

Abstract

West Nile Virus (WNV), an emerging and re-emerging RNA virus, is the leading source of arboviral encephalitic morbidity and mortality in the United States. WNV infections are acutely controlled by innate immunity in peripheral tissues outside of the central nervous system (CNS) but WNV can evade the actions of interferon (IFN) to facilitate CNS invasion, causing encephalitis, encephalomyelitis, and death. Recent studies indicate that STimulator of INterferon Gene (STING), canonically known for initiating a type I IFN production and innate immune response to cytosolic DNA, is required for host defense against neurotropic RNA viruses. We evaluated the role of STING in host defense to control WNV infection and pathology in a murine model of infection. When challenged with WNV, STING knock out (-/-) mice displayed increased morbidity and mortality compared to wild type (WT) mice. Virologic analysis and assessment of STING activation revealed that STING signaling was not required for control of WNV in the spleen nor was WNV sufficient to mediate canonical STING activation in vitro. However, STING-/- mice exhibited a clear trend of increased viral load and virus dissemination in the CNS. We found that STING-/- mice exhibited increased and prolonged neurological signs compared to WT mice. Pathological examination revealed increased lesions, mononuclear cellular infiltration and neuronal death in the CNS of STING-/- mice, with sustained pathology after viral clearance. We found that STING was required in bone marrow derived macrophages for early control of WNV replication and innate immune activation. In vivo, STING-/- mice developed an aberrant T cell response in both the spleen and brain during WNV infection that linked with increased and sustained CNS pathology compared to WT mice. Our findings demonstrate that STING plays a critical role in immune programming for the control of neurotropic WNV infection and CNS disease.

Indexed as

Virus ReplicationAnimalsCentral Nervous SystemFemaleImmunity, InnateMaleMembrane ProteinsMiceMice, Inbred C57BLMice, KnockoutSTING ProteinViral LoadWest Nile FeverWest Nile virusMembrane ProteinsSting1 protein, mouseSTING Protein

Identifiers

PMID31415679
PMCPMC6695101
OpenAlexW2967505920

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.